Academic Community: "RCT and RWE Are Complementary"

Regulatory Standards Evolving at MFDS and HIRA

"RCT-Centric Clinical Re-Assessment of Choline Alfoscerate Can Be Supplemented"

Real-world evidence (RWE), which evaluates drug efficacy using actual clinical data, is emerging as a new standard for pharmaceutical assessment. This is because RWE can demonstrate the long-term effects of medications that are difficult to verify through randomized controlled trials (RCT) alone, which are conducted under controlled conditions. There is increasing demand that RWE should be considered alongside RCT outcomes in the ongoing clinical re-evaluation of choline alfoscerate (commonly known as "choline preparations").


According to the medical and pharmaceutical industries as of September 18, 2026, RCT is a standard method in which patients are randomly assigned to a drug treatment group or a placebo group, and the results are compared under the same conditions over a fixed period. While considered the gold standard for efficacy assessment, RCTs are limited in terms of subject numbers and duration. By contrast, RWE is based on the analysis of data accumulated during actual clinical practice, such as hospital records or health insurance claim data. It allows evaluation of the outcomes after hundreds of thousands of patients have taken a medication for several years.


The academic community has previously discussed how these two types of evidence should be regarded as complementary. In a paper published in 2018 in the Journal of Korean Medical Science (JKMS), a research team led by Professor Kim Joo-han from Seoul National University College of Medicine stated that RCT and RWE can serve complementary roles. While RCT confirms a drug's efficacy, RWE can be used to assess effectiveness, safety, cost, and prescribing patterns in actual clinical settings.

"Consider Real-World Evidence Too"... Choline Preparations' RWE from 510,000 Patients Reexamined View original image

Discussions are also advancing within regulatory institutions about how to incorporate RWE into pharmaceutical assessments. In June 2026, the Health Insurance Review & Assessment Service (HIRA) established the "Guidelines for Generating Real-World Evidence (RWE) for Drug Performance Evaluation." This serves as a standard for enhancing the reliability of RWE data when evaluating drugs listed for health insurance reimbursement. In 2021, the Ministry of Food and Drug Safety published "Guidelines for Research Using Medical Information Databases," aiming to address the limitations of clinical trials with restricted periods and subjects by supplementing them with real-world data.


Choline preparations are frequently mentioned as examples where discussions on the application of RWE can be put into practice. These medications assist in the synthesis of acetylcholine, a neurotransmitter in the brain. They have traditionally been prescribed to improve cognitive function in patients with mild cognitive impairment (MCI). Clinical re-evaluation is currently underway to verify their effectiveness.


There is RWE covering approximately 510,000 patients for choline preparations. In 2025, a research team at Wonju Severance Christian Hospital analyzed National Health Insurance Service data on about 510,000 MCI patients. The results showed that the group taking choline preparations had a 10.1% lower risk of progression to Alzheimer's disease and a 16.8% lower risk of progression to vascular dementia compared to the group not using the medication.



A neurology specialist noted, "Dementia and mild cognitive impairment progress slowly and present differently in each patient, making it difficult to assess the value of a drug based on a single indicator," adding, "It is necessary to consider both actual clinical data and long-term usage experience in clinical re-evaluation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing